Lajos Pusztai Selected Research

Formaldehyde (Formol)

1/2023	Assessment of stained direct cytology smears of breast cancer for whole transcriptome and targeted messenger RNA sequencing.
2/2021	Targeted RNAseq assay incorporating unique molecular identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samples.
12/2019	Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.
12/2019	The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed paraffin-embedded tissues.
12/2018	CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers.
11/2013	Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.
9/2013	Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.
5/2008	Commercialized multigene predictors of clinical outcome for breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lajos Pusztai Research Topics

Disease

263	Breast Neoplasms (Breast Cancer) 04/2024 - 04/2002
217	Neoplasms (Cancer) 12/2023 - 11/2002
49	Pathologic Complete Response 11/2023 - 06/2005
46	Triple Negative Breast Neoplasms 01/2024 - 03/2008
17	Neoplasm Metastasis (Metastasis) 09/2023 - 07/2004
16	Residual Neoplasm 01/2022 - 04/2004
6	Disease Progression 01/2020 - 03/2006
5	Carcinoma (Carcinomatosis) 10/2015 - 04/2004
3	Peripheral Nervous System Diseases (PNS Diseases) 11/2023 - 01/2022
3	Circulating Neoplastic Cells 01/2023 - 04/2009
3	Inflammation (Inflammations) 07/2022 - 10/2011
3	Inflammatory Breast Neoplasms 11/2013 - 02/2011
2	Hypersensitivity (Allergy) 11/2023 - 01/2013
2	Heart Failure 01/2023 - 06/2005
2	Neutropenia 01/2023 - 01/2013
2	Weight Loss (Weight Reduction) 03/2022 - 07/2018
2	Melanoma (Melanoma, Malignant) 10/2021 - 01/2012
2	Lung Neoplasms (Lung Cancer) 01/2021 - 01/2020
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 10/2004

Drug/Important Bio-Agent (IBA)

61	Estrogen ReceptorsIBA 04/2024 - 03/2003
52	Biomarkers (Surrogate Marker)IBA 01/2024 - 01/2003
44	Hormones (Hormone)IBA 12/2023 - 09/2003
34	Paclitaxel (Taxol)FDA LinkGeneric 12/2023 - 02/2004
31	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2022 - 04/2003
30	Proteins (Proteins, Gene)FDA Link 09/2023 - 01/2003
29	Trastuzumab (Herceptin)FDA Link 12/2023 - 04/2002
29	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2023 - 01/2003
23	AnthracyclinesIBA 09/2023 - 04/2004
20	human ERBB2 proteinIBA 01/2023 - 06/2005
19	Messenger RNA (mRNA)IBA 10/2023 - 06/2005
19	RNA (Ribonucleic Acid)IBA 01/2023 - 06/2003
19	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 12/2006
18	Fluorouracil (Carac)FDA LinkGeneric 06/2018 - 04/2003
16	taxaneIBA 01/2022 - 08/2005
12	Immune Checkpoint InhibitorsIBA 09/2023 - 01/2016
12	ParaffinIBA 01/2023 - 01/2003
11	ErbB Receptors (EGF Receptor)IBA 06/2023 - 04/2004
10	B7-H1 AntigenIBA 09/2023 - 05/2014
10	Epirubicin (Ellence)FDA LinkGeneric 10/2022 - 06/2005
9	Progesterone Receptors (Progesterone Receptor)IBA 12/2023 - 03/2008
9	Lapatinib (GW572016)FDA Link 11/2023 - 11/2005
9	pembrolizumabIBA 11/2023 - 01/2016
9	Estrogens (Estrogen)FDA Link 07/2021 - 07/2003
9	Tamoxifen FDA LinkGeneric 03/2018 - 04/2007
8	durvalumabIBA 01/2024 - 10/2020
8	Phenobarbital (Luminal)FDA Link 12/2023 - 08/2005
8	Formaldehyde (Formol)FDA Link 01/2023 - 05/2008
7	MicroRNAs (MicroRNA)IBA 02/2020 - 08/2010
6	Phosphotransferases (Kinase)IBA 06/2023 - 11/2010
6	Monoclonal AntibodiesIBA 01/2019 - 04/2004
5	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2023 - 05/2014
5	Tumor Biomarkers (Tumor Markers)IBA 10/2021 - 05/2008
5	Capecitabine (Xeloda)FDA Link 01/2021 - 09/2003
5	Docetaxel (Taxotere)FDA Link 11/2012 - 04/2002
4	Epidermal Growth Factor (EGF)IBA 04/2024 - 08/2010
4	CytokinesIBA 11/2023 - 02/2004
4	130-nm albumin-bound paclitaxelIBA 02/2022 - 01/2018
4	Everolimus FDA Link 01/2022 - 07/2014
4	Small Interfering RNA (siRNA)IBA 10/2019 - 11/2010
4	Transcription Factors (Transcription Factor)IBA 07/2018 - 09/2003
4	Investigational DrugsIBA 05/2018 - 07/2012
4	Taxoids (Taxanes)IBA 01/2017 - 07/2004
3	LigandsIBA 11/2023 - 12/2009
3	2- benzylidene- 3- (cyclohexylamino)- 2,3- dihydro- 1H- inden- 1- oneIBA 06/2023 - 12/2015
3	PlatinumIBA 01/2023 - 01/2015
3	Peptides (Polypeptides)IBA 01/2023 - 01/2008
3	Carboplatin (JM8)FDA LinkGeneric 10/2022 - 07/2016
3	Metformin (Glucophage)FDA LinkGeneric 10/2021 - 08/2011
3	atezolizumabIBA 10/2021 - 01/2016
3	Ado-Trastuzumab EmtansineIBA 01/2021 - 10/2016
3	NucleotidesIBA 01/2021 - 01/2015
3	exemestane (Aromasin)FDA Link 01/2021 - 07/2015
3	Bevacizumab (Avastin)FDA Link 01/2020 - 10/2004
3	AntibodiesIBA 01/2016 - 07/2011
3	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 10/2015 - 06/2005
3	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 05/2014 - 01/2008
3	Complementary DNA (cDNA)IBA 01/2006 - 03/2003
3	Peptide Hydrolases (Proteases)FDA Link 03/2004 - 03/2003
2	InterferonsIBA 12/2023 - 01/2022
2	Immunoconjugates (Immunoconjugate)IBA 12/2023 - 10/2019
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 11/2023 - 11/2018
2	veliparibIBA 01/2023 - 07/2016
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2023 - 01/2013
2	Fulvestrant (Faslodex)FDA Link 01/2022 - 01/2018
2	Circulating Tumor DNAIBA 01/2022 - 01/2022
2	ChromatinIBA 01/2022 - 09/2020
2	CateninsIBA 01/2022 - 08/2010
2	N,N- dimethyl- N- hexadecyl- 1- octadecylammonium (DDAC)IBA 02/2021 - 11/2020

Therapy/Procedure

124	Therapeutics 12/2023 - 04/2002
110	Drug Therapy (Chemotherapy) 12/2023 - 11/2002
80	Neoadjuvant Therapy 04/2024 - 11/2002
17	Adjuvant Chemotherapy 06/2023 - 02/2004
16	Immunotherapy 04/2024 - 01/2015
7	Segmental Mastectomy (Lumpectomy) 12/2017 - 10/2006
4	Mastectomy (Mammectomy) 12/2021 - 04/2011
4	Aftercare (After-Treatment) 09/2020 - 11/2002
4	Precision Medicine 12/2018 - 11/2006
3	Radiotherapy 01/2023 - 08/2004
3	Combination Drug Therapy (Combination Chemotherapy) 01/2012 - 01/2010
2	Investigational Therapies (Experimental Therapy) 12/2023 - 11/2021